23rd Aug 2023 09:30
(Alliance News) - Bivictrix Therapeutics PLC on Wednesday said it has been granted a US patent for lead asset BVX001.
The Macclesfield, England-based biotechnology company focusing on cancer therapies said the patent, granted by the US Patent & Trademark Office, "provides ultimate broad protection" for the antibody drug conjugate therapy which targets leukaemia.
On Wednesday, Bivictrix also noted that it expects to be granted a patent from the Japanese Patent Office in the coming weeks. It is currently seeking patent approval in seven countries.
Chief Executive Officer Tiffany Thorn said: "This patent grant is expected to be the first of many as we continue to prosecute the wider patent family in seven further jurisdictions worldwide, creating a robust patent protected portfolio."
Shares in Bivictrix were up 1.5% at 13.20 pence each in London on Wednesday morning.
By Sabrina Penty, Alliance News reporter
Comments and questions to [email protected]
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Related Shares:
BVX.L